VSBLTY, CIC TECHNOLOGIES AGREE TO CROSS LICENSE, CO-DEVELOP ACCESS & SECURITY SOLUTIONS USING MACHINE LEARNING, AI & BIOMETRICS
Philadelphia, PA, June 03, 2019 (GLOBE NEWSWIRE) --
VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt:5VS) (OTC:VSBGF), and CIC Technologies (CIC) have agreed to cross license and integrate new technologies to provide frictionless access control and security solutions according to a joint announcement made today by CIC CEO Sean Ryan and VSBLTY Co-Founder and CEO Jay Hutton. The agreement also includes co-marketing and branding.
According to Memoori Research, the global Access Control Total Addressable Market will reach $10.10 billion by 2022 with a compound annual growth rate of 8.04%*.
CIC Technologies’ Virtual Guardian™ combines various security solutions to create a layered security envelope. The focus of the new suite will be on providing comprehensive turnkey security and employee authentication solutions while delivering critical operational analytics to be used to protect both front and back of house access to stadiums, public venues, transportation hubs, houses of worship and schools. Under the agreement CIC will license certain elements of the VSBLTY Vector™ and DataCaptor™ solutions.
CIC is a full-service technology company with expanded business operations in the areas of biometrics authentication solutions and products that provide enhanced security. CIC’s layered approach to security creates a safer environment for employees and patrons. New products such as CIC’s dual authentication, and concealed weapons detection (CWD) coupled with existing products provide for a secure, high throughput ingress.
As explained by CIC president and owner, Sean Ryan, “Having dual authentication enables the ability to primarily identify a target (person) from a distance. And then, using a second modality as the individual arrives at the entry point, to either grant or deny access. Dual authentication eliminates credential sharing, and positively identifies the person moving to an entry point. It also can to be used with existing access control systems.”
Continuing, Ryan said, “The concealed weapons detection system is a set of sensors that can be placed in inconspicuous places to identify weapons (guns, knives, explosive devices) concealed on a person advancing between the sensors. It is a high throughput system, and offers discreet blending into the surrounding environment.”
VSBLTY is a leading retail software and technology company that offers facial recognition and non-occluded weapon detection using the power of machine learning and computer vision. Its proprietary VSBLTY Vector™ product can be used alone or in combination with any type of digital signage and other forms to provide security by looking for “persons of interest” or individuals carrying weapons with the intent to cause harm. VSBLTY’s latest innovation using Intel’s OpenVINO™ platform delivers Edge processing, providing faster and more affordable technology than legacy systems.
“In order to anticipate cyber and physical attacks there increasingly must be a reliance on innovative technologies. We are excited to work with VSBLTY and its state-of-the-art software that provides facial recognition, analytics and weapon detection that, combined with our own biometric, and access control solutions, will take layered security to new and heightened levels for corporations, governments, transportation centers, entertainment and sports venues and schools,” according to Ryan.
“The combination of CIC’s unique concealed weapons detection technology and the VSBLTY optical weapons detection provides a comprehensive weapons detection capacity to allow accurate detection and early warning,” Hutton said, “that is why we are confident that this partnership will result in immediate contract wins and revenue to VSBLTY.”
“With more and more so-called soft targets being attacked around the world, heightened security is needed virtually everywhere. We see CIC Technologies’ innovative security solutions as the ideal environment for VSBLTY’s facial recognition to enable faster, professional security responses to threats and deliver on a critical security market need. This agreement with CIC Technologies will significantly advance the increasingly important need to provide security where it has never been available before,” Hutton added.
*Source: Memoori Research https://memoori.com/market-size-major-trends-access-control-market-2017-2022/
MarketSmart Communications Inc.
CONTACT: Linda Rosanio, 609-472-0877
About VSBLTY (www.vsblty.net)
Headquartered in Philadelphia, VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS)(OTC:VSBGF), is the world leader in Proactive Digital Display™, which transforms retail and public spaces as well as place-based media networks with SaaS-based audience measurement and security software that uses artificial intelligence and machine learning.
CONTACT: Sean Ryan, 973-479-3907
About CIC Technologies (www.getcictech.com )
A full-service security technology company based in Nashville, CIC Technologies provides highly skilled and reliable engineering and proven technical solutions. CIC assists clients with their vision, both in the private and public sectors. The company brings cutting edge technology to life, providing clients the opportunity to maximize their integration. CIC also has expanded business operations in the areas of biometrics authentication solutions and access control products that provide layered security enhancement.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CEST | Pressemelding
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients
Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CEST | Pressemelding
LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CEST | Pressemelding
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle
iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CEST | Pressemelding
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CEST | Pressemelding
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CEST | Pressemelding
Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi